SCHEMBL535892

SCHEMBL535892

CCc1ccccc1[C]=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.45
GABRB2 P47870 4/20 0.45
FFAR1 O14842 1/20 0.41
MGLL Q99685 1/20 0.39
MAPT P10636 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TP53 P04637 1/20 0.36
CYP2D6 P10635 1/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
CTSB P07858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL910448 0.84 DAO (0.38) GABRA1GABRB2FFAR1MAPTCYP2D6
SCHEMBL27249197 0.82 FFAR1 (0.54) GABRA1GABRB2FFAR1MGLLMAPT
SCHEMBL1141490 0.82 GABRA1 (0.45) GABRA1GABRB2FFAR1MGLLMAPT
SCHEMBL2119420 0.81 CYP3A4 (0.44) MAPTCYP2D6
SCHEMBL1049567 0.79 GABRA1 (0.45) GABRA1GABRB2FFAR1MGLL
SCHEMBL9849127 0.79 GABRA1 (0.45) GABRA1GABRB2FFAR1MGLL
SCHEMBL7528264 0.79 TSHR (0.44) GABRA1GABRB2MAPTL3MBTL1CYP2D6
SCHEMBL1584216 0.79 LIPG (0.50)
SCHEMBL7672866 0.79 L3MBTL1 (0.34) GABRA1GABRB2FFAR1MAPTNPSR1
SCHEMBL873220 0.78 FFAR1 (0.44) FFAR1MAPTL3MBTL1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 614 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11596716-B2 Compounds and matrices for use in bone growth and repair HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2023-03-07 US claimed
CN-114933620-A Azithromycin derivatives having epithelial barrier enhancing properties 艾比恩多制药有限责任公司 2022-08-23 CN claimed
CN-114681473-A Application of glucosamine and derivatives thereof as anti-novel coronavirus drugs 南湖实验室 2022-07-01 CN claimed
CN-108290919-B Azithromycin derivatives having epithelial barrier enhancing properties 艾比恩多制药有限责任公司 2022-06-17 CN claimed
US-20220106349-A1 Compounds EPIENDO PHARMACEUTICALS EHF (IS) 2022-04-07 US claimed
US-11236120-B2 Azithromycin derivatives with epithelial barrier enhancement properties EPIENDO PHARMACEUTICALS EHF (IS) 2022-02-01 US claimed
US-20210138117-A1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2021-05-13 US claimed
CN-112336733-A Application of glucosamine and derivatives thereof as anti-novel coronavirus drugs 南湖实验室 2021-02-09 CN claimed
EP-3038621-B1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR HUMAN BIOMOLECULAR RES INSTITUTE (US) 2020-12-02 EP claimed
US-20200317710-A1 Azithromycin Derivatives With Epithelial Barrier Enhancement Properties EPIENDO PHARMACEUTICALS EHF (IS) 2020-10-08 US claimed
US-5843946-A α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 1998-12-01 US claimed
EP-0815069-A1 METHOD FOR SYNTHESISING 2-ETHYL-ANTHRAQUINONE ELF ATOCHEM S.A. (FR) 1998-01-07 EP claimed
EP-0810209-A2 Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 1997-12-03 EP claimed
WO-1996028410-A1 METHOD FOR SYNTHESISING 2-ETHYL-ANTHRAQUINONE ELF ATOCHEM S.A. (FR) 1996-09-19 WO claimed
EP-0715618-A1 HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1996-06-12 EP claimed
EP-0656887-A1 HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1995-06-14 EP claimed
WO-1995006030-A1 HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1995-03-02 WO claimed
WO-1994004492-A1 HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1994-03-03 WO claimed
US-4727079-A Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides UNIVERSITY OF FLORIDA (US) 1988-02-23 US claimed
US-3988345-A HYPOTENSIVE AGENTS; PHOSPHORUS OXYCHLORIDE CHEMIE LINZ AKTIENGESELLSCHAFT (OE) 1976-10-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11596716-B2 Compounds and matrices for use in bone growth and repair BMP2, BMP4, BMP6 GABRA1 4588/4885GABRB2 3615/4885FFAR1 4328/4885
US-20220106349-A1 Compounds CFTR, AQP1, CTSA GABRA1 4809/4885GABRB2 4718/4885FFAR1 4475/4885
US-11236120-B2 Azithromycin derivatives with epithelial barrier enhancement properties CFTR, AQP1, CTSA GABRA1 4781/4885GABRB2 4699/4885FFAR1 4627/4885
US-20210138117-A1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR BMP2, BMP4, BMP6 GABRA1 4588/4885GABRB2 3615/4885FFAR1 4328/4885
US-20200317710-A1 Azithromycin Derivatives With Epithelial Barrier Enhancement Properties CFTR, AQP1, CTSA GABRA1 4781/4885GABRB2 4699/4885FFAR1 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.